Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
JAGX | US
0.07
6.03%
Healthcare
Biotechnology
30/06/2024
16/10/2024
1.23
1.21
1.25
1.19
Jaguar Health Inc. a commercial stage pharmaceuticals company focuses on developing prescription medicines for people and animals with gastrointestinal distress specifically chronic and debilitating diarrhea. The company operates through two segments Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients and to address rare/orphan disease indications including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition it develops NP-300 a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco California.
View LessStrength based on increasing price with high volume
Strong P/E, and PEG ratio indicator
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
72.3%1 month
86.6%3 months
143.4%6 months
5525.2%0.26
-
0.68
1.76
0.56
-0.63
2.91
-0.02
-29.43M
11.37M
11.37M
-
-264.50
-
1.70
-290.94
1.56
4.47
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.23
Range1M
0.35
Range3M
3.48
Rel. volume
1.75
Price X volume
642.19K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 0.6791 | 12.22M | -8.11% | 0.00 | 17.19% |
DOMH | DOMH | Biotechnology | 1.94 | 12.18M | 6.59% | n/a | 7.66% |
BioRestorative Therapies Inc | BRTX | Biotechnology | 1.73 | 11.97M | 0.00% | n/a | 0.77% |
Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 2.18 | 11.59M | 2.83% | n/a | -27.28% |
Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.459 | 11.54M | -1.29% | n/a | 9.67% |
Immuron Limited | IMRN | Biotechnology | 2.01 | 11.45M | 7.49% | n/a | 1.37% |
Common Stock | ADXN | Biotechnology | 10.55 | 11.28M | 0.96% | n/a | 0.25% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.3334 | 11.10M | 1.00% | n/a | 6.82% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.25 | 10.93M | -0.77% | n/a | 1.15% |
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.49 | 10.87M | 4.81% | n/a | 65.80% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.5 | 0 | 1.42% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.05 | 0 | 6.06% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.77 | 0 | 1.65% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.63 | 0.53 | Cheaper |
Ent. to Revenue | 2.91 | 4,005.99 | Cheaper |
PE Ratio | 0.26 | 40.42 | Cheaper |
Price to Book | 0.68 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 143.36 | 72.92 | Riskier |
Debt to Equity | 1.76 | -1.24 | Expensive |
Debt to Assets | 0.56 | 0.25 | Expensive |
Market Cap | 11.37M | 3.78B | Emerging |